Moshe talpaz biography of abraham

At the start of his tenure at The University of Texas MD Anderson Cancer Center as a postdoctoral fellow from to followed by a stint as a clinical fellow from to at that institution, Moshe Talpaz, MD, devoted a significant amount of time to evaluating interferon-alpha (IFN-α) in the frontline treatment for chronic myeloid leukemia (CML).

Though findings from early studies demonstrated long-term survival benefit, the adverse events associated with the agent proved to be detrimental.

Tyrosine kinase inhibitors (TKIs) now enjoy frontline approval, yet the role of interferon continues to be explored.

As a result of ongoing research involving the agent, the FDA approved ropeginterferon alfa-2b (Besremi) in to treat adults with polycythemia vera (PV).¹

Talpaz, a professor of internal medicine at the University of Michigan Rogel Cancer Center in Ann Arbor, feels a certain level of accomplishment with the approval: “I’m very